859 related articles for article (PubMed ID: 32330603)
1. Epitranscriptomics in liver disease: Basic concepts and therapeutic potential.
Zhao Z; Meng J; Su R; Zhang J; Chen J; Ma X; Xia Q
J Hepatol; 2020 Sep; 73(3):664-679. PubMed ID: 32330603
[TBL] [Abstract][Full Text] [Related]
2. The role of m
Chen XY; Zhang J; Zhu JS
Mol Cancer; 2019 May; 18(1):103. PubMed ID: 31142332
[TBL] [Abstract][Full Text] [Related]
3. Epitranscriptomics in fibroblasts and fibrosis.
Ilieva M; Uchida S
Am J Physiol Cell Physiol; 2022 Jun; 322(6):C1110-C1116. PubMed ID: 35508185
[TBL] [Abstract][Full Text] [Related]
4. m
Takemoto S; Nakano M; Fukami T; Nakajima M
Biochem Pharmacol; 2021 Nov; 193():114766. PubMed ID: 34536357
[TBL] [Abstract][Full Text] [Related]
5. N (6)-Methyladenosine (m(6)A) Methylation in mRNA with A Dynamic and Reversible Epigenetic Modification.
Wu R; Jiang D; Wang Y; Wang X
Mol Biotechnol; 2016 Jul; 58(7):450-9. PubMed ID: 27179969
[TBL] [Abstract][Full Text] [Related]
6. The role of m6A modification in the biological functions and diseases.
Jiang X; Liu B; Nie Z; Duan L; Xiong Q; Jin Z; Yang C; Chen Y
Signal Transduct Target Ther; 2021 Feb; 6(1):74. PubMed ID: 33611339
[TBL] [Abstract][Full Text] [Related]
7. The potential role of RNA N6-methyladenosine in Cancer progression.
Wang T; Kong S; Tao M; Ju S
Mol Cancer; 2020 May; 19(1):88. PubMed ID: 32398132
[TBL] [Abstract][Full Text] [Related]
8. FTO, m
Mauer J; Jaffrey SR
FEBS Lett; 2018 Jun; 592(12):2012-2022. PubMed ID: 29754392
[TBL] [Abstract][Full Text] [Related]
9. m
Huff S; Tiwari SK; Gonzalez GM; Wang Y; Rana TM
ACS Chem Biol; 2021 Feb; 16(2):324-333. PubMed ID: 33412003
[No Abstract] [Full Text] [Related]
10. Role of identified RNA N6-methyladenosine methylation in liver.
Xu K; Sun Y; Sheng B; Zheng Y; Wu X; Xu K
Anal Biochem; 2019 Aug; 578():45-50. PubMed ID: 31075230
[TBL] [Abstract][Full Text] [Related]
11. m
Cui Q; Shi H; Ye P; Li L; Qu Q; Sun G; Sun G; Lu Z; Huang Y; Yang CG; Riggs AD; He C; Shi Y
Cell Rep; 2017 Mar; 18(11):2622-2634. PubMed ID: 28297667
[TBL] [Abstract][Full Text] [Related]
12. Role of N
Deng X; Su R; Feng X; Wei M; Chen J
Curr Opin Genet Dev; 2018 Feb; 48():1-7. PubMed ID: 29040886
[TBL] [Abstract][Full Text] [Related]
13. Chemical Inhibitors Targeting the Oncogenic m
Huang Y; Xia W; Dong Z; Yang CG
Acc Chem Res; 2023 Nov; 56(21):3010-3022. PubMed ID: 37889223
[TBL] [Abstract][Full Text] [Related]
14. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC.
Cheng W; Li M; Zhang L; Zhou C; Yu S; Peng X; Zhang W; Zhang W
Front Pharmacol; 2022; 13():973116. PubMed ID: 36120320
[TBL] [Abstract][Full Text] [Related]
15. The Role of Dynamic m
Robinson M; Shah P; Cui YH; He YY
Photochem Photobiol; 2019 Jan; 95(1):95-104. PubMed ID: 29729018
[TBL] [Abstract][Full Text] [Related]
16. Identification of pathology-specific regulators of m
Li N; Zhan X
EPMA J; 2020 Sep; 11(3):485-504. PubMed ID: 32849929
[TBL] [Abstract][Full Text] [Related]
17. The dual role of N6-methyladenosine modification of RNAs is involved in human cancers.
He L; Li J; Wang X; Ying Y; Xie H; Yan H; Zheng X; Xie L
J Cell Mol Med; 2018 Oct; 22(10):4630-4639. PubMed ID: 30039919
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic and Tumor-Suppressive Functions of the RNA Demethylase FTO.
Zuidhof HR; Calkhoven CF
Cancer Res; 2022 Jun; 82(12):2201-2212. PubMed ID: 35303057
[TBL] [Abstract][Full Text] [Related]
19. FTO: An Emerging Molecular Player in Neuropsychiatric Diseases.
Annapoorna PK; Iyer H; Parnaik T; Narasimhan H; Bhattacharya A; Kumar A
Neuroscience; 2019 Oct; 418():15-24. PubMed ID: 31442565
[TBL] [Abstract][Full Text] [Related]
20. m
Liu J; Ren D; Du Z; Wang H; Zhang H; Jin Y
Biochem Biophys Res Commun; 2018 Aug; 502(4):456-464. PubMed ID: 29842885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
